RAPP EDWARD J

SEC source: 0001193125-26-420688 · ownership.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,428

F1 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as a non-emolpyee director in Q3 2026. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 60,584 unvested RSUs.

SEC source: 0001171780-26-000014 · form4-10022026_051002.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,568

Underlying: Common Stock · 129 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001193125-26-303481 · ownership.xml · nonDerivative · entry 2

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,614

F3 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest on the earlier of (i) the first anniversary of the Grant date and (ii) the day before the Company's 2027 Annual Meeting, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date.

F2 · balance_after: Includes 60,584 unvested RSUs

SEC source: 0001193125-26-303481 · ownership.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,030

F1 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as a non-employee director and as Audit Committee Chair in the second quarter of 2026. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 60,584 unvested RSUs

SEC source: 0001171780-26-000012 · form4-07022026_050703.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,236

Underlying: Common Stock · 134 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001171780-26-000010 · form4-05122026_050518.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,964

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · balance_after: Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly.

SEC source: 0001171780-26-000008 · wk-form4_1776204201.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,360

F1 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as Audit Committee Chair and a Director in the first quarter of 2026. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 62,377 unvested RSUs.

SEC source: 0001171780-26-000006 · form4-04022026_050408.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,865

Underlying: Common Stock · 155 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001171780-26-000004 · wk-form4_1768351987.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,178

F1 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as Audit Committee Chair in the fourth quarter of 2025. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 62,377 unvested RSUs.

SEC source: 0001171780-26-000002 · form4-01052026_050107.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,498

Underlying: Common Stock · 147 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001171780-25-000006 · wk-form4_1760475582.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,777

F1 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as Audit Committee Chair in Q3 2025. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 62,377 unvested RSUs.

SEC source: 0001171780-25-000004 · form4-10022025_051003.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,152

Underlying: Common Stock · 145 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-25-000101 · wk-form4_1752525169.xml · nonDerivative · entry 2

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,894

F3 · shares: The shares reported in this transaction represent RSUs that were issued to the Reporting Person in lieu of the cash retainer for the Reporting Person's service as Audit Committee Chair in Q2 2025. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 62,377 unvested RSUs.

SEC source: 0001819493-25-000101 · wk-form4_1752525169.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,293

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest on the earlier of (i) the first anniversary of the Grant date and (ii) the day before the Company's 2026 Annual Meeting, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date

F2 · balance_after: Includes 62,377 unvested RSUs.

SEC source: 0001415889-25-019107 · form4-07022025_050706.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,785

Underlying: Common Stock · 177 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-012792 · form4-05132025_050501.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,458

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · balance_after: Includes an additional 1,899 shares which, due to an administrative error, were inadvertently omitted from a previously filed form.

SEC source: 0001819493-25-000056 · wk-form4_1746055802.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,916

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement and were issued to the director in lieu of their cash retainer for the director's service as in Q1 2025. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 28,694 unvested RSUs.

SEC source: 0001415889-25-009690 · form4-04022025_050409.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,361

Underlying: Common Stock · 155 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-25-000010 · wk-form4_1736908999.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,099

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement and were issued to the Reporting Person in lieu of their cash retainer for the director service in Q4 2024. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 28,694 unvested RSUs.

SEC source: 0001819493-25-000029 · wk-form4a_1740604946.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,509

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement and were issued to the Reporting Person in lieu of their cash retainer for the director service in Q4 2024. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 28,694 unvested RSUs.

SEC source: 0001415889-25-000520 · form4-01032025_050105.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,976

Underlying: Common Stock · 182 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-24-000206 · wk-form4_1734466648.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,034

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement and were issued to the director in lieu of their cash retainer for the director's service in Q3 2024. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 28,694 unvested RSUs.

SEC source: 0001415889-24-024453 · form4-10022024_051010.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,544

Underlying: Common Stock · 164 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-24-000115 · wk-form4_1720830081.xml · nonDerivative · entry 2

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,969

F3 · shares: Represents RSUs issued to the director in lieu of their cash retainer for the director's service in Q2 2024. The RSUs reported vested immediately on the date of grant.

F2 · balance_after: Includes 29,330 unvested RSUs.

SEC source: 0001819493-24-000115 · wk-form4_1720830081.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,252

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest on the earlier of (i) the first anniversary of the Grant date and (ii) the day of the Company's 2025 Annual Meeting, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date.

F2 · balance_after: Includes 29,330 unvested RSUs.

SEC source: 0000897069-24-001473 · form4.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,170

Underlying: Common Stock · 225 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-012528 · form4-05072024_100531.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,356

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001819493-24-000052 · wk-form4_1712960091.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,558

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q1 2024. Each RSU represents a contingent right to receive one share of common stock upon settlement.

F2 · balance_after: Includes 15,450 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-24-009801 · form4-04022024_050405.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,701

Underlying: Common Stock · 212 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-24-000012 · wk-form4_1705525972.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,113

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q4 2023. Each RSU represents a contingent right to receive one share of common stock upon settlement.

F2 · balance_after: On December 6th, the common stock of Xos, Inc. reverse split 1-for-30, resulting in a decrease of 680,452 shares in the reporting person's ownership of common stock.

F3 · balance_after: Includes 15,450 unvested RSUs.

SEC source: 0001415889-24-000327 · form4-01032024_050102.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,266

Underlying: Common Stock · 250 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-23-000239 · wk-form4_1697141635.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 703,915

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q3 2023 and calculated as of October 10, 2023.

F2 · balance_after: Includes 482,597 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-23-013896 · form4-10032023_051004.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,750

Underlying: Common Stock · 259 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-23-000190 · wf-form4_168928835313890.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 688,764

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q2 2023 and calculated as of July 11, 2023.

F2 · balance_after: Includes 482,597 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-23-010774 · form4-07052023_050703.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,254

Underlying: Common Stock · 287 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-23-000142 · wf-form4_168677352703877.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 673,613

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs vest on the earlier of (i) the first anniversary of the Grant date and (ii) the day of the Company's 2024 Annual Meeting, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date.

F2 · balance_after: Includes 482,597 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-23-007674 · form4-05092023_090547.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,034

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001819493-23-000068 · wf-form4_168064032451432.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 229,169

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q1 2023 and calculated as of March 31, 2023.

F2 · balance_after: Includes 153,759 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-23-006073 · form4-04042023_050401.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,727

Underlying: Common Stock · 243 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-23-000015 · wf-form4_167355917054636.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,233

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q4 2022 and calculated as of December 31, 2022.

F2 · balance_after: Includes 153,759 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-23-000086 · form4-01032023_100105.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,256

Underlying: Common Stock · 239 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F3 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-22-000174 · wf-form4_167001605632738.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 513,297

F1 · balance_after: Includes 153,759 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001819493-22-000129 · wf-form4_166491420871053.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,297

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer for the director's service in Q3 2022 and calculated as of September 30, 2022.

F2 · balance_after: Includes 172,835 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001415889-22-010247 · form4-10042022_021024.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,806

Underlying: Common Stock · 288 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001819493-22-000101 · wf-form4_166318582141294.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,919

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The restricted stock units vest on the earlier of (i) the first anniversary of the Grant Date and (ii) the day before the next annual meeting of Xos, Inc. following the Grant Date, subject to the Reporting Person's continuous service with Xos, Inc. through the vesting date.

F2 · balance_after: Includes 172,835 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock upon settlement.

SEC source: 0001819493-22-000063 · wf-form4_165973138668210.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,313

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer. 1,908 RSUs were issued for the director's service in Q1 2022 and calculated as of March 31, 2022. 1,908 RSUs were issued for the director's service in Q2 2022 and calculated as of June 30, 2022.

F2 · balance_after: Includes 57,229 unvested RSUs. Each RSU represents a contingent right to receive one share of common stock uponsettlement.

SEC source: 0001415889-22-007379 · form4-07052022_020714.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,296

Underlying: Common Stock · 237 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-22-002930 · edgar.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,584

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-22-002545 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,860

Underlying: Common Stock · 217 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001209191-22-000914 · doc4.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,474

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. The RSUs were issued to the director in lieu of their cash retainer.